The Effect of Cyclophosphamide Chemotherapy on Ovarian AntiMüllerian Hormone Levels in Breast Cancer Patients

Abstract

Objective: To evaluate cyclophosphamide effects on Anti-
Müllerian hormone (AMH) levels in breast cancer patients
treated with cyclophosphamide chemotherapy.
Methods: This cohort prospective study was conducted in
Dr. Wahidin Sudirohusodo Hospital in the Department of Obstetrics
and Gynecology in collaboration with Department of Surgery,
Faculty of Medicice, Universitas Hasanuddin between September
2015 and June 2016. Serum levels of AMH from forty breast cancer
patients received three series of cyclophosphamide chemotherapy
determined by Enzyme Linked Immuno Sorbent Assay (ELISA).
Results: Serum AMH levels decreased significant in the first series
(from 2.092.04 ï­g/ml to o.651.06 ï­g/ml; p<0.05) through the
third series (from 1.531.34 ï­g/ml to 0.50.65 ï­g/ml; p<0.05) of
cyclophosphamide chemotherapy.
Conclusion: AMH levels decreased significant after cyclophosphamide
indicated that cyclosphosphamide decrease ovarian
reserve.
[Indones J Obstet Gynecol 2018; 6-1: 64-67]
Keywords: anti-müllerian hormone, breast cancer, cyclophosphamide,
ovarian reserveObjective: To evaluate cyclophosphamide effects on Anti-
Müllerian hormone (AMH) levels in breast cancer patients
treated with cyclophosphamide chemotherapy.
Methods: This cohort prospective study was conducted in
Dr. Wahidin Sudirohusodo Hospital in the Department of Obstetrics
and Gynecology in collaboration with Department of Surgery,
Faculty of Medicice, Universitas Hasanuddin between September
2015 and June 2016. Serum levels of AMH from forty breast cancer
patients received three series of cyclophosphamide chemotherapy
determined by Enzyme Linked Immuno Sorbent Assay (ELISA).
Results: Serum AMH levels decreased significant in the first series
(from 2.092.04 ï­g/ml to o.651.06 ï­g/ml; p<0.05) through the
third series (from 1.531.34 ï­g/ml to 0.50.65 ï­g/ml; p<0.05) of
cyclophosphamide chemotherapy.
Conclusion: AMH levels decreased significant after cyclophosphamide
indicated that cyclosphosphamide decrease ovarian
reserve.

Keywords: anti-müllerian hormone, breast cancer, cyclophosphamide,
ovarian reserve